Anticoagulant News and Research

RSS

Deep vein thrombosis common in patients with moderate to severe COVID-19

In their paper available on the medRxiv preprint server, researchers from Russia showed that patients with moderate and severe coronavirus disease (COVID-19) have a high incidence of deep vein thrombosis – indicating that they may necessitate an early administration of anticoagulation therapy as a part of their treatment regimen.

15 Jun 2020

Experts outline best way to predict common heart rhythm disorders

Use the right tool for the job. Today experts outline the best way to identify people most likely to develop common and devastating heart rhythm disorders.

15 Jun 2020

Anticardiolipin antibodies and COVID-19

A new study has shown that anticardiolipin antibodies are associated with the novel coronavirus infection or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19.

10 Jun 2020

Incidence of intracerebral hemorrhages increasing in older people, study finds

Brain bleeds called intracerebral hemorrhages remained stable in incidence among all age groups over the past 30 years, but they increased in people 75 and older, according to a new analysis of the Framingham Heart Study. The findings are in JAMA Neurology.

8 Jun 2020

Deep vein clots in critical COVID-19 illness

A new research paper published in the journal JAMA Network Open in May 2020 reports a high incidence of deep vein clots in patients with severe COVID-19 at a single French medical center. This could indicate the need for systematic anticoagulant therapy in these patients as a preventive measure.

31 May 2020

Heparin resistance among COVID-19 patients admitted to ICU

A new study has shown that COVID-19 patients admitted to the Intensive care unit may be resistant to the naturally occurring anticoagulant Heparin. The study titled, “Heparin resistance in COVID‑19 patients in the intensive care unit,” was published in the latest issue of the Journal of Thrombosis and Thrombolysis.

26 May 2020

Fewer COVID-19 patients suffer from stroke than previously reported

Fewer people than previously reported suffer from stroke as a result of COVID-19, a new analysis finds. However, strokes that accompany the pandemic virus, SARS-CoV-2, appear to be more severe.

20 May 2020

COVID-19 associated with high thrombotic risk

COVID-19 is associated with a high incidence of venous thromboembolism, blood clots in the venous circulation, according to a study conducted by researchers at Brighton and Sussex Medical School, UK.

19 May 2020

Study highlights need to focus on medications that address clot formation

Earlier this week, the BBC reported that one-third of COVID-19 patients developed dangerous blood clots.

19 May 2020

COVID-19 may lead to thrombosis in the lungs and subsequently multi organ failure

COVID-19, the disease caused by SARS-CoV-2, not only may lead to severe pneumonia but also to thrombosis in the lungs and, subsequently, to multi organ failure involving kidneys, liver and pancreas.

18 May 2020

COVID-19 patients at high risk for developing complications associated with blood clots

When researchers from the University of Colorado Anschutz Medical Campus, Aurora, used a combination of two specific blood-clotting tests, they found critically ill patients infected with Coronavirus Disease 2019 (COVID-19) who were at high risk for developing renal failure, venous blood clots, and other complications associated with blood clots, such as stroke.

15 May 2020

SARS-CoV-2 binds heparan sulfate, preventing host cell infection

A new study published in May 2020 on the preprint server bioRxiv shows that the SARS-CoV-2 virus can bind to a sugar molecule called heparan sulfate (HS), thereby hindering its entry into the host cell.

12 May 2020

Study provides indications and techniques of lower extremity revascularization

Lower extremity artery disease is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions of people.

7 May 2020

Treating hospitalized COVID-19 patients with anticoagulants may improve their survival chances

Treating hospitalized COVID-19 patients with anticoagulants-;blood thinners that slow down clotting-;may improve their chances of survival, researchers from the Mount Sinai COVID Informatics Center report.

7 May 2020

Study reveals antiviral properties of glycosaminoglycans against SARS-CoV-2

Glycosaminoglycans can inhibit cell invasion by acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other coronaviruses, which supports the utilization of such therapeutics in the fight against coronavirus disease (COVID-19) – reports a new study available on the preprint server bioRxiv.

3 May 2020

Low molecular weight heparins inhibit SARS-CoV-2 cell invasion

A recent paper available on the preprint server bioRxiv* reports preliminary data on the ability of low molecular weight heparins to interact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), elicit structural changes in its key proteins and subsequently halt cell invasion.

3 May 2020

AAN publishes updated practice advisory on closure of common heart defect after stroke

New guidance from the American Academy of Neurology concludes that closure of a common heart defect called a patent foramen ovale may be recommended for some people who have had a stroke.

29 Apr 2020

Trial assesses tissue plasminogen activator as a treatment for COVID-19-related respiratory failure

A new study published online in the Journal of Trauma and Acute Care Surgery in March 2020 reports that the anticoagulation drug tPA could be a potential aid in managing respiratory failure in patients with COVID-19.

8 Apr 2020

Excess cardiac myosin worsens damage to heart tissue during a heart attack

A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

2 Apr 2020

Pancreatitis drug Nafamostat shows promise for coronavirus

With the increasing number of infections across the globe, scientists have resorted to studying existing drugs in the hope of discovering a cure for the coronavirus disease (COVID-19). A team of researchers has found that an existing drug, Nafamostat or Fusan, a drug used to treat acute pancreatitis, may effectively block the process used by the novel coronavirus to spread and cause illness.

1 Apr 2020